Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer

Bibliography

• National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, 1 – 3 November 2000. J Natl Cancer Inst Monogr 2001;2001(30):5-15
   Google Scholar
• Fisher B, Bryant J, Wolmark N, Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8):2672-85
   PubMed Web of Science ®Google Scholar
• Current Trials Working Party of the Cancer Research Campaign in Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88(24):1834-9
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88(21):1543-49
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
   PubMed Web of Science ®Google Scholar
• Hu Z, Fan C, Oh DS, The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369(9555):29-36
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr, Pivot X, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009 (In press)
   Google Scholar
• Kaufman B, Trudeau M, Awada A, Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10(6):581-8
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26(34):5544-52
   PubMed Web of Science ®Google Scholar
• Gennari A, Sormani MP, Pronzato P, HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008;100(1):14-20
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA, c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330(18):1260-6
   PubMed Web of Science ®Google Scholar
• Bryce C, Kennecke H, Chia S, Benefit of paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer. J Clin Oncol 2003;21(23):4465
   PubMed Web of Science ®Google Scholar
• Ahmed MI, Lennard TWJ. Breast cancer: role of neoadjuvant therapy. Int J Surg 2009 (In press)
   Google Scholar
• Chow LW, Yip AY, Loo WT, Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111(1-2):13-7
   PubMed Web of Science ®Google Scholar
• Johnston SR. Clinical trials of intracellular signal transductions inhibitors for breast cancer–a strategy to overcome endocrine resistance. Endocr Relat Cancer 2005;12 (Suppl 1):S145-S157
   PubMed Web of Science ®Google Scholar
• Chow LW, Yip AY, Loo WT, Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Lett 2008;262(2):232-8
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK, A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(3):R25
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34
   PubMed Web of Science ®Google Scholar
• Gianni L, Zambetti M, Clark K, Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23(29):7265-77
   PubMed Web of Science ®Google Scholar
• Albain K, Barlow W, O'Malley F, Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100-(SWOG 8814). San Antonio Breast Cancer Symposium; 2004
   Google Scholar
• Forbes JF, Cuzick J, ; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53
   PubMed Web of Science ®Google Scholar
• Mumby PB, Lo SS, Norton J, Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. Presented at the 30th San Antonio Breast Cancer Symposium, 13 – 16 December 2007
   Google Scholar
• Lo SS, Norton J, J Mumby PB, Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. J Clin Oncol 2007;25(Suppl): abstract 577
   Google Scholar
• Oratz R, Paul D, Cohn A, Impact of Oncotype DX on decision making in breast cancer clinical practice. Breast Cancer Res Treat 2006;100(Suppl 1):S100
   Google Scholar
• Kamal AH, Loprinzi CL, Reynolds C, How well do standard prognostic criteria predict oncotype DX (ODX) scores? J Clin Oncol 2007;25(Suppl): abstract 576
   Google Scholar